DM
n=74 (%)
PM
n=20 (%)
OS
n=24 (%)
Prednisone
<40 mg/day
>40 mg/day
71 (96)
17 (23)
54 (73)
20 (100)
3 (15)
17 (85)
24 (100)
9 (37)
15 (63)
Cytotoxic drugs
MTX <15mg/week
MTX >15mg/week
AZA <50 mg/day
AZA >50 mg/day
Both
Cyclophosphamide
63 (85)
18 (24)
7 (10)
0
22 (30)
12 (16)
4 (5)
16 (80)
7 (35)
2 (10)
0
2 (10)
4 (20)
1 (5)
18 (75)
4 (17)
2 (8)
2 (8)
5 (21)
4 (17)
1 (4)
Chloroquine 37 20 0
Functional status at first visit
I
II
III
IV
V
3 (4)
32 (43)
30 (41)
9 (12)
0
1 (5)
7 (35)
11 (55)
1 (5)
0
0
9 (37)
11 (46)
4 (17)
0
Functional status at last visit
I
II
III
IV
V
55 (74)
8 (11)
2 (3)
2 (3)
7 (9)
13 (65)
5 (25)
1 (5)
0
1(5)
16 (67)
3 (12)
0
1 (4)
4 (17)
Response to therapy 63 (85) 18 (90) 19 (79)
Death 7 (9) 1 (5) 4 (17)
Cause of death
Infections
Respiratory failure
Malignancy
Unknown
Cardiovascular
3/7 (43)
1/7 (14)
2/7 (29)
1/7 (14)
0
1/1 (100)
0
0
0
0
2/5 (40)
0
1/5 (20)
1/5 (20)
1/5 (20)
Table 3: Treatment and outcome in 118 patients with Dermatomyositis (DM), Polymyositis (PM) and Overlap Syndrome (OS).